Not sure about that, MSB's cells are already on the market for treatment of aGVHD in Japan and will more than likely be approved in the US soon without needing a partnership. Great news for CYP though, hopefully you avoid making a number of the mistakes MSB has and the path there is somewhat less rocky. CYP has a lot of room to move north with its current MC too.
Theres plenty of room in the market for both companies
Ann: Trading Halt, page-78
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $39.74M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 22.5¢ | 22.0¢ | $29.06K | 131.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 951 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 10000 | 1 |
View Market Depth
| Last trade - 15.59pm 08/11/2024 (20 minute delay) ? |
| CYP (ASX) Chart |